(Q34437548)

2 August 2017

1 reference

title

Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer (English)

1 reference

non-small-cell lung carcinoma

2 August 2017

1 reference

1 reference

1 reference

S Noble

1

1 reference

PubMed ID

9279506

2 August 2017

K L Goa

series ordinal

2

1 reference

2 August 2017

1 September 1997

1 reference

2 August 2017

1 reference

2 August 2017

54

1 reference

2 August 2017

447-472

1 reference

2 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199754030-00009

2 August 2017

0 references

cites work

Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.

1 reference

12 December 2020

2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).

1 reference

12 December 2020

Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation

1 reference

12 December 2020

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

1 reference

12 December 2020

New drugs in the treatment of non-small cell lung cancer.

1 reference

12 December 2020

Treatment of pancreatic cancer: current limitations, future possibilities

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

Schedule-dependent antitumor effect of gemcitabine in in vivo model system

1 reference

12 December 2020

Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors

1 reference

12 December 2020

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

12 December 2020

Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts

1 reference

12 December 2020

Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule

1 reference

12 December 2020

Radiosensitization of human tumor cells by gemcitabine in vitro

1 reference

12 December 2020

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms

1 reference

12 December 2020

Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

1 reference

12 December 2020

Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models

1 reference

12 December 2020

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

12 December 2020

Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer

1 reference

12 December 2020

Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer

1 reference

12 December 2020

Economic value of gemcitabine in non-small cell lung cancer.

1 reference

12 December 2020

Action of 2',2'-difluorodeoxycytidine on DNA synthesis

1 reference

12 December 2020

Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)

1 reference

12 December 2020

Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells

1 reference

12 December 2020

Overview of current and future chemotherapeutic agents in non-small cell lung cancer.

1 reference

12 December 2020

Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu

1 reference

12 December 2020

Aggressive vs nonaggressive therapy for metastatic NSCLC.

1 reference

12 December 2020

Chemotherapy for non-small cell lung cancer

1 reference

12 December 2020

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer

1 reference

12 December 2020

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

1 reference

12 December 2020

Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review

1 reference

12 December 2020

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

1 reference

12 December 2020

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

1 reference

12 December 2020

Economic considerations in the care of lung cancer patients.

1 reference

12 December 2020

Safety profile of gemcitabine

1 reference

12 December 2020

Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts

1 reference

12 December 2020

Quality-of-life and cost-effectiveness assessment in lung cancer

1 reference

12 December 2020

Radiosensitization of human solid tumor cell lines with gemcitabine

1 reference

12 December 2020

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

12 December 2020

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

12 December 2020

Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.

1 reference

12 December 2020

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study

1 reference

12 December 2020

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

12 December 2020

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

12 December 2020

The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.

1 reference

12 December 2020

Gemcitabine safety overview.

1 reference

12 December 2020

Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).

1 reference

12 December 2020

Chemotherapy versus best supportive care for advanced non-small-cell lung cancer

1 reference

12 December 2020

Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.

1 reference

12 December 2020

No standard treatment is available for advanced pancreatic cancer.

1 reference

12 December 2020

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team

1 reference

12 December 2020

Treatment of metastatic non-small cell lung cancer

1 reference

12 December 2020

Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine

1 reference

12 December 2020

Gemcitabine: preclinical pharmacology and mechanisms of action.

1 reference

12 December 2020

Synergistic interaction between cisplatin and gemcitabine in vitro.

1 reference

12 December 2020

Chemotherapy of adenocarcinoma of the pancreas

1 reference

12 December 2020

Clinical, toxicological and pharmacological aspects of gemcitabine

1 reference

12 December 2020

Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units

1 reference

12 December 2020

Interaction between cisplatin and gemcitabine in vitro and in vivo.

1 reference

12 December 2020

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1 reference

12 December 2020

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

1 reference

12 December 2020

Clinical pharmacokinetics of anti-metabolites.

1 reference

12 December 2020

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer

1 reference

12 December 2020

Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event

1 reference

12 December 2020

Is the use of chemotherapy justified in non-small-cell lung cancer?

1 reference

12 December 2020

Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.

1 reference

12 December 2020

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

12 December 2020

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

12 December 2020

Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer

1 reference

12 December 2020

Placental transfer, lacteal transfer and plasma protein binding of gemcitabine

1 reference

12 December 2020

Chemotherapy for pancreatic carcinoma

1 reference

12 December 2020

Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells

1 reference

12 December 2020

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

12 December 2020

Gemcitabine: safety profile unaffected by starting dose

1 reference

12 December 2020

A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer

1 reference

12 December 2020

An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.

1 reference

12 December 2020

Combination chemotherapy studies with gemcitabine

1 reference

12 December 2020

Preclinical characteristics of gemcitabine.

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity

1 reference

12 December 2020

Gemcitabine and radiosensitization in human tumor cells

1 reference

12 December 2020

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer

1 reference

12 December 2020

Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer

1 reference

12 December 2020

[A late phase II study of LY188011 (Gemcitabine hydrochloride) in patients with non-small-cell lung cancer. Gemcitabine Cooperative Study Group B for Late Phase II]

1 reference

12 December 2020

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

12 December 2020

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

12 December 2020

10.2165/00003495-199754030-00009

Identifiers

DOI

1 reference

PubMed ID

9279506

Dimensions Publication ID

2 August 2017

0 references

1 reference

PubMed ID

9279506